Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00103935 · ClinicalTrials.gov registry record · Phase 2
Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT00103935 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 45 participants.
The verdict
NCT00103935, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
Exenatide LAR is a long-acting release formulation of exenatide, which is a twice-daily dosage form currently under investigation as a potential treatment for people with type 2 diabetes mellitus. This study will assess the safety, tolerability, and pharmacokinetics of Exenatide LAR administered weekly by subcutaneous injection in people with type 2 diabetes mellitus.
Interventions
- DRUG placebo
- DRUG Exenatide LAR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2005-02 |
| Est. Completion | 2005-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00103935
The ClinicalTrials.gov registry entry for NCT00103935 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00103935 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00103935 about?
NCT00103935 is a clinical study titled "Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes". Exenatide LAR is a long-acting release formulation of exenatide, which is a twice-daily dosage form currently under investigation as a potential treatment for people with type 2 diabetes mellitus. This study will assess the safety, tolerability, and pharmacokinetics of Exenatide LAR administered wee...
What is the current status of trial NCT00103935?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2005-02. Estimated completion is 2005-10.
What interventions are being tested in trial NCT00103935?
The interventions under investigation include: placebo (DRUG), Exenatide LAR (DRUG).
Who is sponsoring clinical trial NCT00103935?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.